Neoadjuvant chemotherapy (NAC) is widely used in patients with TNBC, but there are significant differences in the efficacy of chemotherapy in different patients. Stromal tumor infiltrating lymphocytes (sTILs) have been widely studied as biomarkers reflecting the therapeutic effect of NAC. As a tumor-associated gene, UBR5 has been found to be associated with chemotherapy sensitivity and prognosis of many cancers. This is the first time that we have combined UBR5 and sTILs to evaluate the chemotherapy efficacy of patients with TNBC treated with NAC and to study the correlation between sTILs and UBR5. MethodsSPSS was used to analyze the correlation between UBR5 and sTILs and clinicopathological data. Then doxorubicin and mitoxantrone treated mouse breast cancer cells to explore the relationship between UBR5 expression and chemotherapeutic drug sensitivity. Finally, R language analyzes the relationship between UBR5 and immune-related genes and immune score.ResultsIn patients with TNBC treated with NAC, the expression level of UBR5 and the degree of infiltration of sTILs are independent factors that affect whether the patient can achieve PCR and the expression between the two is negatively correlated. UBR5 expression can cause mouse breast cancer cells to develop resistance to doxorubicin and mitoxantrone. At the same time, UBR5 is also highly correlated with a variety of immune-related genes and immune scores.ConclusionUBR5 and sTILs can jointly predict the efficacy of NAC in patients with TNBC. At the same time, the expression of UBR5 is also an important reason for chemotherapy resistance in patients with TNBC.
Archived Files and Locations
|application/pdf 664.6 kB ||
access all versions, variants, and formats of this works (eg, pre-prints)